2526 — Hangzhou Diagens Biotechnology Co Income Statement
0.000.00%
Last trade - 00:00- HK$20.80bn
- HK$20.75bn
- CNY164.42m
Annual income statement for Hangzhou Diagens Biotechnology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 52.8 | 70.4 | 164 |
| Cost of Revenue | |||
| Gross Profit | 37.5 | 46.1 | 118 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 92.7 | 92.5 | 231 |
| Operating Profit | -39.9 | -22.1 | -66.6 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -56.2 | -43.4 | -67.1 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -56.1 | -43.4 | -67.1 |
| Net Income Before Extraordinary Items | |||
| Net Income | -56.1 | -43.4 | -67.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -56.1 | -43.4 | -67.1 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.632 | -0.489 | -0.59 |